Skip to main content
Premium Trial:

Request an Annual Quote

ActivX Wins $1.1M SBIR for Protein Activity/Toxicity Database

NEW YORK, June 30 - ActivX Biosciences has received a three-year, $1.1 million Phase II Small Business Innovation Research award from the National Cancer Institute, the company said today.


ActivX will use the grant to build a database of changes in protein activity that result from toxicant exposure. The database, which will allow scientists to compare protein activity profiles of lead compounds with those of known toxic agents, will be used to evaluate candidate drug compounds, the company said.


The company will use its high-throughput protein analysis platform to create the database, and will retain worldwide rights to any inventions made in the course of this project.


The award provides $493,000 for the first year with additional funding of $558,000 scheduled over the second and third years. It follows on a $155,000, six-month Phase I SBIR grant ActivX received in August 2002 to initiate drug toxicity profiling.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.